| |
著者: Takahiko Hara, Jun Nishijima, Yoshihiro Miyachika, Yoshiaki Yamamoto, Shigeru Sakano, Hideyasu Matsuyama
雑誌名: Jpn J Clin Oncol. 2011 Jul;41(7):902-7. doi: 10.1093/jjco/hyr064. Epub 2011 May 25.
Abstract/Text
BACKGROUND: Bladder preservation therapy (BPT) has been attempted for patients with localized muscle-invasive bladder cancer. However, the indication for BPT has not yet been established. To identify patients who are good candidates for BPT, we evaluated our long-term experience with chemoradiation therapy (CRT) for bladder preservation.
METHODS: Between 1994 and 2009, 82 patients with bladder cancer (clinical stage T2-N0M0) without concurrent upper urinary tract urothelial cancer were treated with CRT. Before CRT, the patients had a biopsy or resection of the tumor by transurethral resection (TUR). The response to CRT was evaluated by TUR, urine cytology and computed tomography.
RESULTS: Thirty-two cases (39.0%) had a pathological complete response (pCR) that was defined as no microscopic residual tumor in the bladder. After TUR, 69 cases (84.0%) achieved local control of the cancer, which was considered as a clinical complete response (cCR). There was no significant association between achievement of pCR and examined parameters. The long-term results of CRT were evaluated in cCR cases. The median follow-up was 42.8 months (range, 4.1-155.1). The 5-year overall survival rate was 77.7% and 5-year progression-free survival rate was 64.5%. Clinical T stage and type of tumor (primary or recurrence) were predictive factors for overall survival as well as progression-free survival. In addition, primary cT2 cases had significantly better prognosis than cT3-4 and recurrent cases in overall survival and progression-free survival (P= 0.008 and P= 0.046, respectively).
CONCLUSION: Cases with a primary cT2 tumor could be good candidates for BPT with radiation combined with cisplatin.
PMID 21616918 Jpn J Clin Oncol. 2011 Jul;41(7):902-7. doi: 10.1093/jjco/hyr064. Epub 2011 May 25.
|
